Your browser is no longer supported. Please, upgrade your browser.
Settings
ACRX [NASD]
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.77 Insider Own0.90% Shs Outstand43.72M Perf Week-9.88%
Market Cap163.51M Forward P/E- EPS next Y-0.80 Insider Trans0.00% Shs Float42.97M Perf Month-58.26%
Income-33.40M PEG- EPS next Q-0.30 Inst Own82.20% Short Float21.36% Perf Quarter-43.42%
Sales5.20M P/S31.44 EPS this Y-30.50% Inst Trans1.63% Short Ratio14.45 Perf Half Y-44.35%
Book/sh1.07 P/B3.50 EPS next Y22.30% ROA-34.70% Target Price8.07 Perf Year-69.12%
Cash/sh1.72 P/C2.17 EPS next 5Y- ROE-58.80% 52W Range3.66 - 12.39 Perf YTD-44.43%
Dividend- P/FCF- EPS past 5Y5.80% ROI-52.70% 52W High-69.81% Beta2.40
Dividend %- Quick Ratio5.60 Sales past 5Y- Gross Margin- 52W Low2.19% ATR0.43
Employees50 Current Ratio5.60 Sales Q/Q-99.30% Oper. Margin- RSI (14)23.62 Volatility6.51% 7.82%
OptionableYes Debt/Eq0.53 EPS Q/Q-178.00% Profit Margin- Rel Volume1.04 Prev Close3.87
ShortableYes LT Debt/Eq0.39 EarningsMar 09 AMC Payout- Avg Volume635.01K Price3.74
Recom2.60 SMA20-33.79% SMA50-43.57% SMA200-48.35% Volume657,935 Change-3.36%
Mar-10-15Reiterated RBC Capital Mkts Outperform $12 → $8
Mar-09-15Downgrade Mizuho Buy → Neutral $14 → $5.59
Feb-26-15Upgrade Mizuho Neutral → Buy $6 → $14
Nov-06-14Downgrade Mizuho Buy → Neutral $15 → $6
Sep-26-14Downgrade ROTH Capital Buy → Neutral
Jul-28-14Reiterated RBC Capital Mkts Outperform $15 → $12
Jul-28-14Reiterated Mizuho Buy $20 → $15
Jul-28-14Downgrade Canaccord Genuity Buy → Hold
Apr-17-14Initiated Canaccord Genuity Buy $16
Jan-07-14Initiated RBC Capital Mkts Outperform $15
Dec-19-13Reiterated Mizuho Buy $18 → $20
Dec-17-13Reiterated MLV & Co Buy $15 → $16.50
Jul-17-13Reiterated Mizuho Neutral $13 → $18
Feb-04-13Initiated MLV & Co Buy $13
Jan-30-13Initiated Mizuho Buy $13
Oct-10-12Resumed Canaccord Genuity Buy $8
May-26-11Initiated Canaccord Genuity Buy $6
Mar-23-15 12:15PM  AcelRx Pharmaceuticals: What Went Wrong and What's on the Horizon for the Struggling Biotech? at TheStreet
07:33AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Mar-20-15 04:27PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors
03:27PM  AcelRx Appoints Howard B. Rosen as Interim CEO at noodls
03:00PM  AcelRx Appoints Howard B. Rosen as Interim CEO PR Newswire
Mar-17-15 02:00PM  AcelRx Starts Pivotal Study on Acute Pain Management Drug - Analyst Blog
Mar-16-15 07:23AM  AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04 at noodls
07:00AM  AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04 PR Newswire
Mar-14-15 09:20AM  8 Analyst Stocks Under $10 With Massive Upside Calls at 24/7 Wall St.
Mar-13-15 06:26PM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AcelRx Pharmaceuticals, Inc. (ACRX) To Contact The Firm PR Newswire
06:11AM  ACELRX PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
Mar-10-15 12:21PM  AcelRx Pharmaceuticals (ACRX) Stock Extends Losses Today as Jefferies Downgrades at TheStreet -15.70%
11:55AM  Jefferies Downgrades AcelRx Pharmaceuticals After FDA Requests Additional Clinical Trial For Lead Drug Zalviso
08:55AM  Top Analyst Upgrades and Downgrades: AcelRx, AECOM, EA, HP, Myriad, Urban Outfitters and More at 24/7 Wall St.
Mar-09-15 10:10PM  AcelRx Pharma Meets Expectations, But Says It Won't Submit New Zalviso Application -36.96%
05:39PM  AcelRx Pharmaceuticals reports 4Q loss
04:14PM  AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results at noodls
04:05PM  AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results PR Newswire
03:40PM  EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against AcelRx Pharmaceuticals, Inc. ACRX Business Wire
03:28PM  AcelRx Pharmaceuticals (ACRX) Stock Tanks Today on FDA Demand For Further Zalviso Trials at TheStreet
10:25AM  Can AcelRx Overcome Yet Another FDA Roadblock? at 24/7 Wall St.
10:24AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. - ACRX PR Newswire
08:53AM  AcelRx Says FDA Calls for Additional Trial on Zalviso at The Wall Street Journal
07:45AM  FDA asks AcelRx for additional trial on pain drug Reuters
07:30AM  AcelRx Provides Regulatory Update on Zalviso PR Newswire
Mar-06-15 08:46AM  Should You Sell AcelRx Pharmaceuticals (ACRX) Before Earnings? - Tale of the Tape Zacks
Mar-04-15 07:00AM  AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 PR Newswire
Feb-26-15 06:07AM  AcelRx upgraded by Mizuho Briefing.com
Feb-24-15 07:03AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Feb-20-15 07:00AM  AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events PR Newswire
Feb-13-15 04:31PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Feb-09-15 06:07AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Feb-04-15 07:00AM  AcelRx Pharmaceuticals to Present at BIO CEO & Investor Conference PR Newswire
Jan-15-15 09:59AM  Will the Second Time be a Charm for Biotech AcelRx After Their FDA Rejection? at TheStreet -6.09%
Jan-13-15 04:50PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur EDGAR Online
Dec-16-14 05:05PM  AcelRx Pharmaceuticals Announces Departure of Richard A. King, President And CEO Benzinga
05:01PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K/A, Change in Directors or Principal Officers, Financial Statements and EDGAR Online
Dec-15-14 06:26AM  La Jolla Pharmaceutical (LJPC) Jumps: Stock Gains 5.8% Zacks
Dec-08-14 06:06AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
05:58AM  Why AcelRx Pharmaceuticals (ACRX) Could Be Positioned for a Surge? Zacks
Dec-02-14 07:00AM  AcelRx Pharmaceuticals Receives CE Mark Approval for Zalviso PR Newswire
Nov-21-14 06:47PM  EQUITY ALERT: Rosen Law Firm P.A. Reminds AcelRx Pharmaceuticals, Inc. Investors of Important December 1, 2014 Class Action Deadline- ACRX GlobeNewswire
Nov-20-14 10:32AM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Business Wire
08:16AM  Zacks Rank #1 Additions for Thursday Zacks
07:00AM  AcelRx Pharmaceuticals to Participate in Four Upcoming Investor Events PR Newswire
Nov-19-14 09:42PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit Business Wire
Nov-18-14 01:04PM  ACELRX PHARMACEUTICALS INC Financials EDGAR Online Financials
Nov-17-14 06:48PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 Business Wire
Nov-13-14 04:16PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:00AM  AcelRx Pharmaceuticals Announces Zalviso Sublingual Sufentanil Data Presentation At The American Society Of Regional Anesthesia And Pain Medicine Meeting PR Newswire
Nov-12-14 07:09PM  10-Q for AcelRx Pharmaceuticals, Inc. Company Spotlight
09:04AM  AcelRx Pharmaceuticals (ACRX) Upgraded From Sell to Hold at TheStreet
Nov-11-14 12:00PM  AcelRx Pharmaceuticals (ACRX) Stock Rises After Third-Quarter Earnings Report at TheStreet +14.93%
08:14AM  Zacks Rank #1 Additions for Tuesday Zacks
06:17AM  ArQule (ARQL) Catches Eye: Stock Jumps 10.4% Zacks
05:44AM  Regulus Slumps: RGLS Falls 5.3% in Session Zacks
Nov-10-14 06:30PM  AcelRx Pharmaceuticals posts 3Q profit AP
05:12PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or EDGAR Online
04:01PM  AcelRx Pharmaceuticals Reports Third Quarter 2014 Financial Results PR Newswire
07:07AM  Q3 2014 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close CCBN
07:00AM  AcelRx Pharmaceuticals Receives International Standards Organization (ISO) 13485:2003 Certification of its Quality Management System PR Newswire
Nov-07-14 07:00AM  AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events PR Newswire +7.28%
Nov-06-14 03:34PM  INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Business Wire -9.34%
07:00AM  AcelRx Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Monday, November 10, 2014 PR Newswire
Nov-05-14 04:00PM  Acelrx Pharmaceuticals Announces Management Change PR Newswire -5.48%
Oct-31-14 05:05PM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $50,000 Investing in AcelRx Pharmaceuticals, Inc. (ACRX) to Contact the Firm GlobeNewswire
Oct-29-14 01:04PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in AcelRx Pharmaceuticals, Inc. to Contact Brower Piven Before the December 1, 2014 Lead Plaintiff Deadline in Class Action Lawsuit - GlobeNewswire
07:53AM  Can The Uptrend Continue for AcelRx Pharmaceuticals (ACRX)? Zacks
Oct-27-14 04:27PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 -- ACRX Marketwired
07:00AM  AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentations At The American College Of Surgeons Meeting PR Newswire
Oct-22-14 02:40PM  EQUITY ALERT: Rosen Law Firm P.A. Reminds AcelRx Pharmaceuticals, Inc. Investors of Important Class Action Deadline - ACRX GlobeNewswire
07:00AM  AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results PR Newswire
Oct-20-14 12:42PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 -- ACRX GlobeNewswire
Oct-16-14 07:00AM  AcelRx Pharmaceuticals Provides Update on its Patent Portfolio for Zalviso and its Proprietary Platform Technologies PR Newswire +6.83%
Oct-15-14 08:26PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit Business Wire +6.17%
Oct-10-14 07:30PM  Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against AcelRx Pharmaceuticals, Inc. -- ACRX GlobeNewswire
06:37PM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $50,000 Investing in AcelRx Pharmaceuticals, Inc. (ACRX) to Contact the Firm Marketwired
07:00AM  AcelRx Pharmaceuticals Announces Multiple Sublingual Sufentanil Data Presentations At The American Society Of Anesthesiologists Meeting PR Newswire
Oct-08-14 01:52PM  Robbins Arroyo LLP: AcelRx Pharmaceuticals, Inc. (ACRX) Misled Shareholders According to a Recently Filed Class Action GlobeNewswire
Oct-07-14 08:35PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in AcelRx Pharmaceuticals, Inc. to Contact Brower Piven Before the December 1, 2014 Lead Plaintiff Deadline in Class Action Lawsuit - GlobeNewswire
08:00PM  Harwood Feffer LLP Announces Investigation of AcelRx Pharmaceuticals, Inc. PR Newswire
06:31PM  Lifshitz & Miller Law Firm Announces Investigation of AcelRx Pharmaceuticals, Inc., Ambit Biosciences, Athlon Energy Inc., LipoScience, Inc., Simplicity Bancorp, Inc., and TIBCO Software Inc. PR Newswire
11:10AM  AcelRx Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors Business Wire
Oct-06-14 05:54PM  Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Marketwired
02:21PM  EQUITY ALERT: The Rosen Law Firm P.A. Announced Filing of Securities Class Action Against AcelRx Pharmaceuticals, Inc. - ACRX GlobeNewswire
02:08PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 -- ACRX GlobeNewswire
07:00AM  Sufentanil sublingual tablet system study results to be presented at the International Association for the Study of Pain Meeting PR Newswire
Oct-03-14 07:15PM  INVESTOR ALERT: Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Announced by Law Offices of Howard G. Smith Business Wire
04:00PM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In AcelRx Pharmaceuticals, Inc. (ACRX) To Contact The Firm PR Newswire
Oct-02-14 10:32AM  INVESTOR ALERT: Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Filed By Glancy Binkow & Goldberg LLP Business Wire
Sep-29-14 02:45PM  SHAREHOLDER ALERT: Investigation on Behalf of AcelRx Pharmaceuticals, Inc. Investors Announced by Law Offices of Howard G. Smith Business Wire +9.06%
10:40AM  INVESTOR ALERT: Investigation on Behalf of AcelRx Pharmaceuticals, Inc. Shareholders Announced by Glancy Binkow & Goldberg LLP Business Wire
Sep-26-14 04:35PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online -19.49%
03:23PM  Why AcelRx Pharmaceuticals (ACRX) Stock Hit a One-Year Low Today at TheStreet
11:22AM  Midday movers: Apple, RadioShack, Shutterfly & more at CNBC
09:34AM  [$$] AcelRx Shares Slide on FDA Delay at The Wall Street Journal
07:00AM  AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso PR Newswire
Sep-10-14 07:00AM  AcelRx Announces Publication of Manuscript Analyzing Cost of Intravenous Patient-Controlled Analgesia with Opioids PR Newswire
Sep-04-14 07:00AM  AcelRx Announces Publication of Sufentanil Sublingual Tablet System vs. Intravenous Patient-Controlled Analgesia with Morphine for Postoperative Pain Study Results PR Newswire
Aug-27-14 07:00AM  AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events PR Newswire
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company's lead product candidate is Zalviso, an investigational, pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in the hospital setting. The company is also developing ARX-04, a sufentanil single-dose tablet, which has been planned to initiate Phase III clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as in the emergency room, hospital floor, ambulatory care facilities, or on the battlefield. In addition, its product candidate pipeline consists of ARX-02, a pain management system that has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a single, fixed-dose, and combination drug product, which has been completed Phase II clinical trial designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Palmer Pamela PChief Medical OfficerMar 12Option Exercise1.3225,00033,000370,015Mar 17 03:58 PM